James Percy Daniels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James Percy Daniels has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Stephen J. Freedland
Department of Urology, Cedars-Sinai Medical Center, Los Angeles, USA
7 shared publications - Nadine A. Friedrich
Department of Urology, Cedars-Sinai Medical Center, Los Angeles, USA
5 shared publications - Gloria Cecilia Galvan
Department of Urology, Cedars-Sinai Medical Center, Los Angeles, USA
4 shared publications Sanjay Das
Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, USA
2 shared publications- Sanjay Das
Durham Veterans Affairs Health Care System, Department of Surgery, Durham, NC; Department of Urology, University of California - Los Angeles, Los Angeles, CA; Department of Urology, Cedars-Sinai Medical Center, Los Angeles
2 shared publications - Timothy John Daskivich
Department of Urology, Cedars-Sinai Medical Center, Los Angeles, USA
2 shared publications
Latest Publications
- 8 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3) , e2500199
Integrating Natural Language Processing With ChatGPT to Improve Quality of Artificial Intelligence Summaries of Prostate Cancer Consultations.
Patients with prostate cancer (PC) face complex treatment decisions and often struggle to recall information from consultations. Artificial intelligence(AI)-generated summaries have potential to improve recall, but summaries of key concepts from unstructured transcripts often lack focus and quality. We investigated whether natural language processing (NLP) preprocessing before AI summarization improves topic concordance and quality of risk information in AI summaries. We audio-recorded and transcribed 42 PC consultations. Validated NLP models identified sentences about 5 content areas important for PC decision making: cancer prognosis (CP), life expectancy (LE), erectile dysfunction (ED), irritative urinary symptoms (IUS), and urinary incontinence (UI). ChatGPT-4.0 summarized raw transcripts and NLP-identified sentences across NLP probability thresholds from 50% to 90%. Summaries were reviewed for topic concordance, quality of risk information, and risk quantification. Logistic regression evaluated associations of these outcomes with NLP thresholds. We analyzed 1,260 ChatGPT-4.0 summaries (6 per topic across 42 consultations). For each 10% increase in NLP probability threshold, the proportion of topic-related sentences in ChatGPT summaries increased by 18% for ED (incidence rate ratio [IRR], 1.18, 95% CI, 1.1 to 1.2), 16% for UI (IRR, 1.16, 95% CI, 1.1 to 1.1), 31% for IUS (IRR, 1.31; 95% CI, 1.2 to 1.3), 30% for LE (IRR, 1.30, 95% CI, 1.2 to 1.3), and 12% for CP (IRR, 1.12, 95% CI, 1.1 to 1.1). Odds of risk quantification increased for LE (odds ratio [OR], 1.39, 95% CI, 1.26 to 1.54, P < .001) and UI (OR, 1.18, 95% CI, 1.08 to 1.28, P < .001). Quality of risk information significantly increased for LE (0.16 points, 95% CI, 0.12 to 0.20) for each 10% increase in NLP threshold, with a clinically meaningful change (1 point) at a 60% threshold. NLP preprocessing improves topic concordance, quality of risk information, and quantification in AI summaries of select content areas important for PC decision making, with potential to improve clinical care.
- 8 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3) , e2500199
Integrating Natural Language Processing With ChatGPT to Improve Quality of Artificial Intelligence Summaries of Prostate Cancer Consultations.
Patients with prostate cancer (PC) face complex treatment decisions and often struggle to recall information from consultations. Artificial intelligence(AI)-generated summaries have potential to improve recall, but summaries of key concepts from unstructured transcripts often lack focus and quality. We investigated whether natural language processing (NLP) preprocessing before AI summarization improves topic concordance and quality of risk information in AI summaries. We audio-recorded and transcribed 42 PC consultations. Validated NLP models identified sentences about 5 content areas important for PC decision making: cancer prognosis (CP), life expectancy (LE), erectile dysfunction (ED), irritative urinary symptoms (IUS), and urinary incontinence (UI). ChatGPT-4.0 summarized raw transcripts and NLP-identified sentences across NLP probability thresholds from 50% to 90%. Summaries were reviewed for topic concordance, quality of risk information, and risk quantification. Logistic regression evaluated associations of these outcomes with NLP thresholds. We analyzed 1,260 ChatGPT-4.0 summaries (6 per topic across 42 consultations). For each 10% increase in NLP probability threshold, the proportion of topic-related sentences in ChatGPT summaries increased by 18% for ED (incidence rate ratio [IRR], 1.18, 95% CI, 1.1 to 1.2), 16% for UI (IRR, 1.16, 95% CI, 1.1 to 1.1), 31% for IUS (IRR, 1.31; 95% CI, 1.2 to 1.3), 30% for LE (IRR, 1.30, 95% CI, 1.2 to 1.3), and 12% for CP (IRR, 1.12, 95% CI, 1.1 to 1.1). Odds of risk quantification increased for LE (odds ratio [OR], 1.39, 95% CI, 1.26 to 1.54, P < .001) and UI (OR, 1.18, 95% CI, 1.08 to 1.28, P < .001). Quality of risk information significantly increased for LE (0.16 points, 95% CI, 0.12 to 0.20) for each 10% increase in NLP threshold, with a clinically meaningful change (1 point) at a 60% threshold. NLP preprocessing improves topic concordance, quality of risk information, and quantification in AI summaries of select content areas important for PC decision making, with potential to improve clinical care.
- 1 January 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 211 (1) , 101-110
Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study
Though the pathogenesis of benign prostatic hyperplasia is unclear, it was previously believed that increasing androgen levels contributed, though not all data support this idea. We tested if elevated serum testosterone or dihydrotestosterone were risk factors for lower urinary tract symptoms incidence in asymptomatic men and for lower urinary tract symptoms progression in symptomatic men. A post hoc analysis of REDUCE was performed in 3009 asymptomatic men and in 2145 symptomatic men. REDUCE was a randomized trial of dutasteride for prostate cancer prevention in men with an elevated prostate-specific antigen and negative prestudy biopsy. We estimated multivariable adjusted hazard ratios and 95% confidence intervals using Cox models to test the association between quintiles of serum testosterone and dihydrotestosterone at baseline and lower urinary tract symptoms incidence and progression and tested for interaction by treatment arm (dutasteride vs placebo). In asymptomatic men, there was no evidence serum testosterone or dihydrotestosterone were related to lower urinary tract symptoms incidence (P = .9, P = .4). In symptomatic men, there was no evidence serum testosterone or dihydrotestosterone were related to lower urinary tract symptoms progression (P = .9, P = .7). Results were similar in both placebo and dutasteride arms (all P interaction ≥ .3). In REDUCE, higher serum testosterone and higher serum dihydrotestosterone were not associated with either lower urinary tract symptoms incidence in asymptomatic men or lower urinary tract symptoms progression in symptomatic men. These data do not support the hypothesis that serum androgens in middle-aged men are associated with lower urinary tract symptoms.
- 1 January 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 211 (1) , 101-110
Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study
Though the pathogenesis of benign prostatic hyperplasia is unclear, it was previously believed that increasing androgen levels contributed, though not all data support this idea. We tested if elevated serum testosterone or dihydrotestosterone were risk factors for lower urinary tract symptoms incidence in asymptomatic men and for lower urinary tract symptoms progression in symptomatic men. A post hoc analysis of REDUCE was performed in 3009 asymptomatic men and in 2145 symptomatic men. REDUCE was a randomized trial of dutasteride for prostate cancer prevention in men with an elevated prostate-specific antigen and negative prestudy biopsy. We estimated multivariable adjusted hazard ratios and 95% confidence intervals using Cox models to test the association between quintiles of serum testosterone and dihydrotestosterone at baseline and lower urinary tract symptoms incidence and progression and tested for interaction by treatment arm (dutasteride vs placebo). In asymptomatic men, there was no evidence serum testosterone or dihydrotestosterone were related to lower urinary tract symptoms incidence (P = .9, P = .4). In symptomatic men, there was no evidence serum testosterone or dihydrotestosterone were related to lower urinary tract symptoms progression (P = .9, P = .7). Results were similar in both placebo and dutasteride arms (all P interaction ≥ .3). In REDUCE, higher serum testosterone and higher serum dihydrotestosterone were not associated with either lower urinary tract symptoms incidence in asymptomatic men or lower urinary tract symptoms progression in symptomatic men. These data do not support the hypothesis that serum androgens in middle-aged men are associated with lower urinary tract symptoms.
- 8 September 2023
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 27 (3) , 457-461
Relative search popularity of five advanced prostate cancer medications using Google Trends
Background There are many FDA-approved drugs for advanced prostate cancer (PC), yet public interest in these drugs is not well understood. We compared public interest and state-level predictors of interest in five common oral adjunctive hormonal therapies. Methods Google Trends™ was queried for: “Enzalutamide”, “Abiraterone Acetate”, “Bicalutamide”, “Apalutamide”, and “Darolutamide” in the United States from January 2004 to November 2022. Data are presented as relative search index (RSI) by month. RSI ranges from 0 to 100 with 100 being peak popularity, 50 being half of the peak popularity, and 0 representing insufficient data to be determined. Results Several drugs abruptly increased in popularity following FDA approval including abiraterone, enzalutamide, and apalutamide. All drugs decreased in popularity from January 2020 to July 2020, corresponding with the COVID-19 pandemic. In the most recent 5 years, enzalutamide and abiraterone were the most common searched drugs, with bicalutamide a close 3rd place. States that did not expand Medicaid were significantly more likely to have bicalutamide as the top search drug vs. states that expanded Medicaid (p = 0.012). Across all states with data (n = 39), higher bicalutamide RSIs were significantly associated with lower household income (r = 0.385, p = 0.02) and greater percent of uninsured adults (r = 0.426, p = 0.007). This is the first study using Google Trends to compare advanced PC drugs by search popularity. Conclusions Despite the emergence of more effective medications, bicalutamide remains relatively popular, particularly in states with lower household income, more uninsured adults, or those that did not expand Medicaid, possibly due to its lower cost.
- 8 September 2023
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 27 (3) , 457-461
Relative search popularity of five advanced prostate cancer medications using Google Trends
Background There are many FDA-approved drugs for advanced prostate cancer (PC), yet public interest in these drugs is not well understood. We compared public interest and state-level predictors of interest in five common oral adjunctive hormonal therapies. Methods Google Trends™ was queried for: “Enzalutamide”, “Abiraterone Acetate”, “Bicalutamide”, “Apalutamide”, and “Darolutamide” in the United States from January 2004 to November 2022. Data are presented as relative search index (RSI) by month. RSI ranges from 0 to 100 with 100 being peak popularity, 50 being half of the peak popularity, and 0 representing insufficient data to be determined. Results Several drugs abruptly increased in popularity following FDA approval including abiraterone, enzalutamide, and apalutamide. All drugs decreased in popularity from January 2020 to July 2020, corresponding with the COVID-19 pandemic. In the most recent 5 years, enzalutamide and abiraterone were the most common searched drugs, with bicalutamide a close 3rd place. States that did not expand Medicaid were significantly more likely to have bicalutamide as the top search drug vs. states that expanded Medicaid (p = 0.012). Across all states with data (n = 39), higher bicalutamide RSIs were significantly associated with lower household income (r = 0.385, p = 0.02) and greater percent of uninsured adults (r = 0.426, p = 0.007). This is the first study using Google Trends to compare advanced PC drugs by search popularity. Conclusions Despite the emergence of more effective medications, bicalutamide remains relatively popular, particularly in states with lower household income, more uninsured adults, or those that did not expand Medicaid, possibly due to its lower cost.
- Open Access
- 16 August 2023
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 115 (12) , 1448-1450
The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?
Obesity tends to fan the flames of cancer in multiple organs by way of increasing incidence, promoting progression, and decreasing survival ( 1). With respect to prostate cancer, obesity is often tied to an increased risk of mortality and advanced disease, though the last notion is still debated. Questions remain about what causes the association between obesity and advanced prostate cancer; whether obesity propagates a molecular mechanism that drives aggressive prostate cancer; or whether obesity leads to delayed diagnoses that are left unchecked, resulting in patients ultimately presenting with more advanced disease. Prostate-specific antigen (PSA)–based prostate cancer screening has certainly saved many lives, but it remains controversial and possibly underutilized because of concerns about overdiagnosis and overtreatment (ie, the “harms” from widespread screening). Although some research suggests that obese patients are more likely to undergo PSA screening, we also know that PSA levels from people with a higher body mass index (BMI) are diluted, giving them a false sense of security ( 2). All this begs the question: if annual prostate cancer screening were universal, would prostate cancer still be associated with a higher risk of advanced prostate cancer and related mortality? In this issue of the Journal, Hurwitz and colleagues ( 3) seek to answer this question using a unique study population.
- 16 August 2023
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 115 (12) , 1448-1450
Open AccessThe growing implications of obesity for prostate cancer risk and mortality: where do we go from here?
Obesity tends to fan the flames of cancer in multiple organs by way of increasing incidence, promoting progression, and decreasing survival ( 1). With respect to prostate cancer, obesity is often tied to an increased risk of mortality and advanced disease, though the last notion is still debated. Questions remain about what causes the association between obesity and advanced prostate cancer; whether obesity propagates a molecular mechanism that drives aggressive prostate cancer; or whether obesity leads to delayed diagnoses that are left unchecked, resulting in patients ultimately presenting with more advanced disease. Prostate-specific antigen (PSA)–based prostate cancer screening has certainly saved many lives, but it remains controversial and possibly underutilized because of concerns about overdiagnosis and overtreatment (ie, the “harms” from widespread screening). Although some research suggests that obese patients are more likely to undergo PSA screening, we also know that PSA levels from people with a higher body mass index (BMI) are diluted, giving them a false sense of security ( 2). All this begs the question: if annual prostate cancer screening were universal, would prostate cancer still be associated with a higher risk of advanced prostate cancer and related mortality? In this issue of the Journal, Hurwitz and colleagues ( 3) seek to answer this question using a unique study population.
- Open Access
- 8 July 2023
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 27 (1) , 150-152
Investigating trends in interest for benign prostatic hyperplasia surgery options using Google Trends
Understanding patient interest among surgical options is challenging. We used Google Trends to analyze interest in benign prostatic hyperplasia (BPH) surgeries recommended for prostate volumes <80 cc. Google Trends was queried with five BPH surgeries. Final rank of search terms was TURP, UroLift, Rezum, Aquablation, and Greenlight. Google Trends can be an effective tool for evaluating public interest trends in BPH surgery.
- 8 July 2023
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 27 (1) , 150-152
Open AccessInvestigating trends in interest for benign prostatic hyperplasia surgery options using Google Trends
Understanding patient interest among surgical options is challenging. We used Google Trends to analyze interest in benign prostatic hyperplasia (BPH) surgeries recommended for prostate volumes <80 cc. Google Trends was queried with five BPH surgeries. Final rank of search terms was TURP, UroLift, Rezum, Aquablation, and Greenlight. Google Trends can be an effective tool for evaluating public interest trends in BPH surgery.
- Open Access
- 2 February 2023
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 26 (4) , 641-642
A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer
- 2 February 2023
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 26 (4) , 641-642
Open AccessA healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer
- Open Access
- 2 February 2023
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 26 (4) , 639-640
Working hard or hardly working? A brief commentary of latest research on exercise and prostate cancer
- 2 February 2023
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 26 (4) , 639-640
Open AccessWorking hard or hardly working? A brief commentary of latest research on exercise and prostate cancer